The landscape of cancer treatment is continually evolving, bringing new hope to patients worldwide. A significant milestone was achieved with the U.S.
Capivasertib Receives FDA Approval for Advanced HR-Positive, HER2-Negative Breast Cancer
The landscape of cancer treatment is continually evolving, bringing new hope to patients worldwide. A significant milestone was achieved with the U.S. Food and Drug Administration (FDA) approval of capivasertib. This novel AKT inhibitor marks a crucial advancement, offering a targeted therapeutic option for a specific subset of patients battling advanced hormone receptor (HR)-positive, HER2-negative breast cancer.
The Significance of Capivasertib's FDA Approval
On November 16, 2023, the FDA granted accelerated approval to capivasertib, co-packaged with fulvestrant, under the brand name Truqap. This approval is specifically for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have one or more PIK3CA, AKT1, or PTEN alterations, and who have progressed on at least one endocrine-based regimen in the metastatic setting or after recurrence within 12 months of completing adjuvant therapy.
The approval underscores the growing importance of precision medicine, where treatments are tailored to the genetic profile of a patient's tumor. For patients with these specific genomic alterations, capivasertib represents a much-needed addition to their treatment arsenal, potentially overcoming resistance to standard endocrine therapies.
What is Capivasertib and How Does It Work?
An AKT Inhibitor
Capivasertib is an orally administered adenosine triphosphate (ATP) competitive inhibitor of all three AKT isoforms (AKT1, AKT2, and AKT3). The AKT pathway, also known as the PI3K/AKT/PTEN pathway, is a critical signaling cascade within cells that regulates cell growth, proliferation, survival, and metabolism.
In many cancers, including breast cancer, this pathway can become hyperactive due to mutations in genes like PIK3CA or AKT1, or loss of the tumor suppressor PTEN. This hyperactivity drives tumor growth and resistance to therapy. By inhibiting AKT, capivasertib aims to disrupt these pro-cancer signals, thereby reducing tumor cell proliferation and promoting cell death.
The CAPItello-291 Trial: Basis for Approval
The FDA's decision was primarily based on results from the pivotal Phase 3 CAPItello-291 clinical trial. This global, double-blind, randomized, placebo-controlled study evaluated capivasertib in combination with fulvestrant versus placebo with fulvestrant in patients with advanced HR-positive, HER2-negative breast cancer.
The trial demonstrated a statistically significant improvement in progression-free survival (PFS) in the overall population, and particularly in the subgroup of patients whose tumors had PIK3CA, AKT1, or PTEN alterations. For this specific population, capivasertib plus fulvestrant showed a median PFS of 7.3 months compared to 3.1 months for placebo plus fulvestrant, highlighting the targeted efficacy of the drug.
Impact on Breast Cancer Treatment
The approval of capivasertib provides a new, targeted therapeutic avenue for a challenging form of breast cancer. Patients with HR-positive, HER2-negative breast cancer often develop resistance to endocrine therapies over time. The identification of PIK3CA, AKT1, or PTEN alterations can guide treatment decisions, offering a personalized approach.
This development not only offers hope for extending progression-free survival but also emphasizes the importance of biomarker testing in advanced breast cancer to identify patients who are most likely to benefit from this innovative treatment.
The FDA approval of capivasertib represents a significant step forward in the treatment of advanced HR-positive, HER2-negative breast cancer with specific genetic alterations. As research continues to uncover the complexities of cancer, targeted therapies like capivasertib reinforce the power of precision medicine in delivering more effective and personalized treatment options to patients in need.